372 related articles for article (PubMed ID: 25661353)
21. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
22. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
[TBL] [Abstract][Full Text] [Related]
23. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.
Han B; Huang J; Han Y; Hao J; Wu X; Song H; Chen X; Shen Q; Dong X; Pang H; Cai L
Int J Biol Macromol; 2019 Mar; 125():544-556. PubMed ID: 30537505
[TBL] [Abstract][Full Text] [Related]
24. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
25. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
[TBL] [Abstract][Full Text] [Related]
26. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.
Xie X; Hu Y; Xu L; Fu Y; Tu J; Zhao H; Zhang S; Hong R; Gu X
Tumour Biol; 2015 Sep; 36(9):7185-94. PubMed ID: 25894378
[TBL] [Abstract][Full Text] [Related]
27. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222.
Yu DD; Wu Y; Zhang XH; Lv MM; Chen WX; Chen X; Yang SJ; Shen H; Zhong SL; Tang JH; Zhao JH
Tumour Biol; 2016 Mar; 37(3):3227-35. PubMed ID: 26432333
[TBL] [Abstract][Full Text] [Related]
28. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
29. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
30. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways.
Liu C; Xing H; Guo C; Yang Z; Wang Y; Wang Y
Cell Cycle; 2019 Sep; 18(18):2215-2227. PubMed ID: 31286834
[TBL] [Abstract][Full Text] [Related]
31. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells.
Kang Y; Park MA; Heo SW; Park SY; Kang KW; Park PH; Kim JA
Biochim Biophys Acta; 2013 Mar; 1830(3):2638-48. PubMed ID: 23246576
[TBL] [Abstract][Full Text] [Related]
32. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
33. [miR-34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1].
Li X; Zhao J; Tang J
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):892-6. PubMed ID: 25623761
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
[TBL] [Abstract][Full Text] [Related]
36. miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.
Yao YS; Qiu WS; Yao RY; Zhang Q; Zhuang LK; Zhou F; Sun LB; Yue L
Oncol Rep; 2015 May; 33(5):2504-12. PubMed ID: 25813250
[TBL] [Abstract][Full Text] [Related]
37. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Hu D; Li M; Su J; Miao K; Qiu X
Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260
[TBL] [Abstract][Full Text] [Related]
38. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
Jiang L; He D; Yang D; Chen Z; Pan Q; Mao A; Cai Y; Li X; Xing H; Shi M; Chen Y; Bruce IC; Wang T; Jin L; Qi X; Hua D; Jin J; Ma X
FEBS Lett; 2014 May; 588(11):2009-15. PubMed ID: 24786471
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
40. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
